|
Volumn 34, Issue SUPPL. 2, 2010, Pages 99-103
|
Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema
|
Author keywords
Bevacizumab; Diabetic macular oedema
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTIINFLAMMATORY AGENT;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
TRIAMCINOLONE;
ADULT;
AGED;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIABETIC RETINOPATHY;
DRUG COMBINATION;
FEMALE;
FOLLOW UP;
HUMAN;
INTRAVITREAL DRUG ADMINISTRATION;
MALE;
MIDDLE AGED;
RANDOMIZED CONTROLLED TRIAL;
RETINA MACULA EDEMA;
TREATMENT OUTCOME;
ADULT;
AGED;
ANGIOGENESIS INHIBITORS;
ANTI-INFLAMMATORY AGENTS;
ANTIBODIES, MONOCLONAL;
DIABETIC RETINOPATHY;
DRUG THERAPY, COMBINATION;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
INTRAVITREAL INJECTIONS;
MACULAR EDEMA;
MALE;
MIDDLE AGED;
TREATMENT OUTCOME;
TRIAMCINOLONE;
|
EID: 77955595268
PISSN: 03506134
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (12)
|
References (19)
|